Gary Raskob to Venous Thrombosis
This is a "connection" page, showing publications Gary Raskob has written about Venous Thrombosis.
Connection Strength
8.174
-
Association Between Asymptomatic Proximal Deep Vein Thrombosis and Mortality in Acutely Ill Medical Patients. J Am Heart Assoc. 2021 02; 10(5):e019459.
Score: 0.691
-
Extended treatment with edoxaban in cancer patients with venous thromboembolism: A post-hoc analysis of the Hokusai-VTE Cancer study. J Thromb Haemost. 2019 11; 17(11):1866-1874.
Score: 0.620
-
New paradigms in venous thromboprophylaxis of medically ill patients. Thromb Haemost. 2017 08 30; 117(9):1662-1670.
Score: 0.537
-
Edoxaban for treatment of venous thromboembolism in patients with cancer. Rationale and design of the Hokusai VTE-cancer study. Thromb Haemost. 2015 Nov 25; 114(6):1268-76.
Score: 0.472
-
Thrombosis: a major contributor to global disease burden. Arterioscler Thromb Vasc Biol. 2014 Nov; 34(11):2363-71.
Score: 0.447
-
Oral direct factor Xa inhibition with edoxaban for thromboprophylaxis after elective total hip replacement. A randomised double-blind dose-response study. Thromb Haemost. 2010 Sep; 104(3):642-9.
Score: 0.331
-
Surveillance for deep vein thrombosis and pulmonary embolism: recommendations from a national workshop. Am J Prev Med. 2010 Apr; 38(4 Suppl):S502-9.
Score: 0.325
-
Exclusion of first-episode deep-vein thrombosis after-hours using D-dimer. Blood Coagul Fibrinolysis. 2007 Dec; 18(8):795-800.
Score: 0.277
-
Idraparinux versus standard therapy for venous thromboembolic disease. N Engl J Med. 2007 Sep 13; 357(11):1094-104.
Score: 0.273
-
Extended prophylaxis of venous thromboembolism with idraparinux. N Engl J Med. 2007 Sep 13; 357(11):1105-12.
Score: 0.273
-
Negative D-dimer result to exclude recurrent deep venous thrombosis: a management trial. Ann Intern Med. 2004 Dec 07; 141(11):839-45.
Score: 0.225
-
Antithrombotic therapy for venous thromboembolic disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004 Sep; 126(3 Suppl):401S-428S.
Score: 0.221
-
A cost-effectiveness analysis of fondaparinux sodium compared with enoxaparin sodium as prophylaxis against venous thromboembolism: use in patients undergoing major orthopaedic surgery. Pharmacoeconomics. 2004; 22(9):605-20.
Score: 0.211
-
Controversies in timing of the first dose of anticoagulant prophylaxis against venous thromboembolism after major orthopedic surgery. Chest. 2003 Dec; 124(6 Suppl):379S-385S.
Score: 0.210
-
The economics of venous thromboembolism prophylaxis: a primer for clinicians. Chest. 2003 Dec; 124(6 Suppl):393S-396S.
Score: 0.210
-
Measuring the outcomes and pharmacoeconomic consequences of venous thromboembolism prophylaxis in major orthopaedic surgery. Pharmacoeconomics. 2003; 21(7):477-96.
Score: 0.197
-
Sensitivity and specificity of ultrasonography in the diagnosis of upper extremity deep vein thrombosis: a systematic review. Arch Intern Med. 2002 Feb 25; 162(4):401-4.
Score: 0.186
-
Extended out-of-hospital low-molecular-weight heparin prophylaxis against deep venous thrombosis in patients after elective hip arthroplasty: a systematic review. Ann Intern Med. 2001 Nov 20; 135(10):858-69.
Score: 0.182
-
Timing of initial administration of low-molecular-weight heparin prophylaxis against deep vein thrombosis in patients following elective hip arthroplasty: a systematic review. Arch Intern Med. 2001 Sep 10; 161(16):1952-60.
Score: 0.180
-
Effect of Osocimab in Preventing Venous Thromboembolism Among Patients Undergoing Knee Arthroplasty: The FOXTROT Randomized Clinical Trial. JAMA. 2020 01 14; 323(2):130-139.
Score: 0.160
-
Randomized phase 2 trial comparing JNJ-9375, a thrombin-directed antibody, with apixaban for prevention of venous thrombosis. J Thromb Haemost. 2019 12; 17(12):2081-2088.
Score: 0.157
-
Risk Scores for Occult Cancer in Patients with Venous Thromboembolism: A Post Hoc Analysis of the Hokusai-VTE Study. Thromb Haemost. 2018 Jul; 118(7):1270-1278.
Score: 0.143
-
RE-COVERY DVT/PE: Rationale and design of a prospective observational study of acute venous thromboembolism with a focus on dabigatran etexilate. Thromb Haemost. 2017 01 26; 117(2):415-421.
Score: 0.129
-
Global public awareness of venous thromboembolism. J Thromb Haemost. 2015 Aug; 13(8):1365-71.
Score: 0.117
-
Factor XI antisense oligonucleotide for prevention of venous thrombosis. N Engl J Med. 2015 Jan 15; 372(3):232-40.
Score: 0.113
-
On World Thrombosis Day. Lancet. 2014 Nov 08; 384(9955):1653-4.
Score: 0.112
-
Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med. 2010 Dec 23; 363(26):2499-510.
Score: 0.085
-
A dose-finding study with TAK-442, an oral factor Xa inhibitor, in patients undergoing elective total knee replacement surgery. Thromb Haemost. 2010 Dec; 104(6):1150-7.
Score: 0.084
-
Idraparinux versus standard therapy in the treatment of deep venous thrombosis in cancer patients: a subgroup analysis of the Van Gogh DVT trial. Thromb Haemost. 2010 Jul; 104(1):86-91.
Score: 0.082
-
Home therapy of venous thrombosis with long-term LMWH versus usual care: patient satisfaction and post-thrombotic syndrome. Am J Med. 2009 Aug; 122(8):762-769.e3.
Score: 0.078
-
Treatment of venous thromboembolism in patients with cancer: subgroup analysis of the Matisse clinical trials. Thromb Haemost. 2009 Apr; 101(4):762-9.
Score: 0.076
-
A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the Einstein-DVT Dose-Ranging Study. Blood. 2008 Sep 15; 112(6):2242-7.
Score: 0.072
-
Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008 Jun; 133(6 Suppl):454S-545S.
Score: 0.072
-
Prevention of central venous catheter-associated thrombosis: a meta-analysis. Am J Med. 2007 Oct; 120(10):901.e1-13.
Score: 0.068
-
Effect of obesity on outcomes after fondaparinux, enoxaparin, or heparin treatment for acute venous thromboembolism in the Matisse trials. J Thromb Haemost. 2007 Jun; 5(6):1191-4.
Score: 0.067
-
Self-managed long-term low-molecular-weight heparin therapy: the balance of benefits and harms. Am J Med. 2007 Jan; 120(1):72-82.
Score: 0.065
-
Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer. Am J Med. 2006 Dec; 119(12):1062-72.
Score: 0.065
-
Duration of warfarin in pulmonary embolism. Chest. 2006 Jul; 130(1):299; author reply 299-300.
Score: 0.063
-
Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial. Ann Intern Med. 2004 Jun 01; 140(11):867-73.
Score: 0.054
-
Clinical utility of D-dimer in patients with suspected pulmonary embolism and nondiagnostic lung scans or negative CT findings. Chest. 2004 Mar; 125(3):851-5.
Score: 0.053
-
Dose-response study of recombinant factor VIIa/tissue factor inhibitor recombinant nematode anticoagulant protein c2 in prevention of postoperative venous thromboembolism in patients undergoing total knee replacement. Circulation. 2001 Jul 03; 104(1):74-8.
Score: 0.044
-
Predictive value of compression ultrasonography for deep vein thrombosis in symptomatic outpatients: clinical implications of the site of vein noncompressibility. Arch Intern Med. 2000 Feb 14; 160(3):309-13.
Score: 0.040
-
The diagnostic approach to acute venous thromboembolism. Clinical practice guideline. American Thoracic Society. Am J Respir Crit Care Med. 1999 Sep; 160(3):1043-66.
Score: 0.039
-
Rivaroxaban for Thromboprophylaxis after Hospitalization for Medical Illness. N Engl J Med. 2018 Sep 20; 379(12):1118-1127.
Score: 0.036
-
Hemorrhagic complications of anticoagulant treatment. Chest. 2001 Jan; 119(1 Suppl):108S-121S.
Score: 0.011
-
Sensitivity and specificity of helical computed tomography in the diagnosis of pulmonary embolism: a systematic review. Ann Intern Med. 2000 Feb 01; 132(3):227-32.
Score: 0.010
-
Low-molecular-weight heparin vs heparin in the treatment of patients with pulmonary embolism. American-Canadian Thrombosis Study Group. Arch Intern Med. 2000 Jan 24; 160(2):229-36.
Score: 0.010